[Early prostate cancer 2005. New 2005 data].
The Early Prostate Cancer (EPC) Program consists of three randomised, double blind, placebo-controlled trials that assess bicalutamide either as adjuvant to treatment of curative intent or alone (radical prostatectomy, radiotherapy or watchful waiting) in patients with non-metastatic prostate cancer. In total, 8113 men have been enrolled in a 1/1 ratio to receive bicalutamide 150 mg/day orally or a matching placebo. We present the results at a median follow-up. No significant results are yet observed on overall survival in the localised, low-risk disease groups. For patients with locally advanced disease, adjuvant hormonal therapy significantly improves objective progression-free survival over placebo. Moreover, adjuvant bicalutamide offers a significant benefit in terms of overall survival in radiotherapy treated patients for locally advanced prostate cancer.
Fourcade
R-O
RO
Service d'urologie, centre hospitalier, 2, boulevard Verdun, 89000 Auxerre, France. rfourcade@rofuro.fr
D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009570:Nitriles / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000628:therapy; D013997:Time Factors; D014105:Tosyl Compounds / Q000627:therapeutic use*
D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide